SCHEMBL6415037

SCHEMBL6415037

CS(=O)(=O)CNCCn1c(C(N)=O)nc2cc(NCC(=O)c3ccccc3)ccc21

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.39
ALDH1A1 P00352 3/20 0.39
AGTR1 P30556 2/20 0.39
GAA P10253 1/20 0.39
MAPT P10636 1/20 0.39
ACHE P22303 1/20 0.38
AKR1C3 P42330 1/20 0.37
GSK3B P49841 1/20 0.37
RECQL P46063 1/20 0.36
F2 P00734 3/20 0.36
NPC1 O15118 2/20 0.36
RAB9A P51151 2/20 0.36
HPGD P15428 1/20 0.36
CYP2C9 P11712 1/20 0.35
KIF11 P52732 1/20 0.35
JAK2 O60674 3/20 0.35
JAK1 P23458 3/20 0.35
TYK2 P29597 3/20 0.35
JAK3 P52333 3/20 0.35
ITK Q08881 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6414828 0.87 JAK2 (0.45) SMN1; SMN2ALDH1A1AGTR1GAAMAPT
SCHEMBL6416908 0.83 ITK (0.47) ACHEAKR1C3ITKINSR
SCHEMBL6417112 0.82 PTGER4 (0.44) SMN1; SMN2ALDH1A1AGTR1GAAMAPT
SCHEMBL6273358 0.81 ACHE (0.43) SMN1; SMN2ALDH1A1AGTR1GAAMAPT
SCHEMBL6416231 0.81 ITK (0.44) SMN1; SMN2ALDH1A1AGTR1GAAMAPT
SCHEMBL6419529 0.81 SMN1; SMN2 (0.47) SMN1; SMN2ALDH1A1AGTR1GAAMAPT
SCHEMBL6272346 0.80 ACHE (0.39) SMN1; SMN2ALDH1A1AGTR1GAAMAPT
SCHEMBL6277030 0.80 RECQL (0.42) SMN1; SMN2ALDH1A1AGTR1GAAMAPT
SCHEMBL6272962 0.78 HDAC1 (0.43) SMN1; SMN2ALDH1A1AGTR1GAAMAPT
SCHEMBL6419625 0.78 KIF11 (0.47) SMN1; SMN2ALDH1A1AGTR1GAAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050209284-A1 Tec kinase inhibitors BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2005-09-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050209284-A1 Tec kinase inhibitors TEC, ITK, TXK SMN1; SMN2 3626/4885ALDH1A1 3145/4885AGTR1 620/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.